HU195424B - Process for the production of medical solutions containing l-3,4-dihydroxi-phenil-alpha-methil-alanine - Google Patents
Process for the production of medical solutions containing l-3,4-dihydroxi-phenil-alpha-methil-alanine Download PDFInfo
- Publication number
- HU195424B HU195424B HU86268A HU26886A HU195424B HU 195424 B HU195424 B HU 195424B HU 86268 A HU86268 A HU 86268A HU 26886 A HU26886 A HU 26886A HU 195424 B HU195424 B HU 195424B
- Authority
- HU
- Hungary
- Prior art keywords
- solution
- alpha
- methyl
- dopa
- water
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title description 2
- 239000008155 medical solution Substances 0.000 title 1
- 239000000243 solution Substances 0.000 claims abstract description 50
- 239000003186 pharmaceutical solution Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 9
- 239000004327 boric acid Substances 0.000 claims description 9
- 238000010253 intravenous injection Methods 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 5
- 239000002504 physiological saline solution Substances 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 4
- 150000007529 inorganic bases Chemical class 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical class OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 abstract description 21
- 239000013522 chelant Substances 0.000 abstract description 3
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 abstract description 3
- 150000001767 cationic compounds Chemical class 0.000 abstract description 2
- 229910001411 inorganic cation Inorganic materials 0.000 abstract description 2
- 150000002892 organic cations Chemical class 0.000 abstract description 2
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 17
- 230000036772 blood pressure Effects 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- -1 alkyl p-hydroxybenzoate Chemical compound 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU86268A HU195424B (en) | 1986-01-21 | 1986-01-21 | Process for the production of medical solutions containing l-3,4-dihydroxi-phenil-alpha-methil-alanine |
| DE19873701461 DE3701461A1 (de) | 1986-01-21 | 1987-01-20 | Arzneimittelloesung und verfahren zu ihrer herstellung |
| FR878700637A FR2597341B1 (fr) | 1986-01-21 | 1987-01-21 | Solution pharmaceutique contenant de chelates de l-3,4-dihydroxyphenyl-alpha-methylalanine et procede pour la preparation de celle-ci. |
| IT19118/87A IT1201174B (it) | 1986-01-21 | 1987-01-21 | Soluzione farmaceutica comprendente chelati di l-3,4-diidrossifenil-alfa-metilalanina e procedimento per la sua preparazione |
| JP62012184A JPS62228013A (ja) | 1986-01-21 | 1987-01-21 | 血圧降下剤およびその製造方法 |
| AT0010587A AT389227B (de) | 1986-01-21 | 1987-01-21 | Verfahren zur herstellung einer chelatkomplexe von l-3,4-dihydroxyphenyl-alpha-methyl-alaninenthaltenden pharmazeutischen loesung |
| GB8701281A GB2185975B (en) | 1986-01-21 | 1987-01-21 | A pharmaceutical solution comprising chelates of l-3,4-dihydroxyphenyl-alpha-methylalanine and a process for the preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU86268A HU195424B (en) | 1986-01-21 | 1986-01-21 | Process for the production of medical solutions containing l-3,4-dihydroxi-phenil-alpha-methil-alanine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUT42947A HUT42947A (en) | 1987-09-28 |
| HU195424B true HU195424B (en) | 1988-05-30 |
Family
ID=10948826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU86268A HU195424B (en) | 1986-01-21 | 1986-01-21 | Process for the production of medical solutions containing l-3,4-dihydroxi-phenil-alpha-methil-alanine |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS62228013A (de) |
| AT (1) | AT389227B (de) |
| DE (1) | DE3701461A1 (de) |
| FR (1) | FR2597341B1 (de) |
| GB (1) | GB2185975B (de) |
| HU (1) | HU195424B (de) |
| IT (1) | IT1201174B (de) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL124121C (de) * | 1960-04-08 | |||
| US3526698A (en) * | 1968-04-11 | 1970-09-01 | Merck & Co Inc | Stabilization of levo-3-(3,4-dihydroxyphenyl)-2-methylalanine with sodium bisulfite and sorbitol |
| CH545280A (de) * | 1970-10-30 | 1973-12-15 | Hoffmann La Roche | Verfahren zur Herstellung von Phenylalaninderivaten |
| CH552567A (de) * | 1970-10-30 | 1974-08-15 | Hoffmann La Roche | Verfahren zur herstellung von phenylalaninderivaten. |
-
1986
- 1986-01-21 HU HU86268A patent/HU195424B/hu not_active IP Right Cessation
-
1987
- 1987-01-20 DE DE19873701461 patent/DE3701461A1/de active Granted
- 1987-01-21 FR FR878700637A patent/FR2597341B1/fr not_active Expired
- 1987-01-21 IT IT19118/87A patent/IT1201174B/it active
- 1987-01-21 JP JP62012184A patent/JPS62228013A/ja active Granted
- 1987-01-21 GB GB8701281A patent/GB2185975B/en not_active Expired - Lifetime
- 1987-01-21 AT AT0010587A patent/AT389227B/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62228013A (ja) | 1987-10-06 |
| FR2597341B1 (fr) | 1989-05-12 |
| JPH0314808B2 (de) | 1991-02-27 |
| IT8719118A0 (it) | 1987-01-21 |
| GB2185975A (en) | 1987-08-05 |
| IT1201174B (it) | 1989-01-27 |
| ATA10587A (de) | 1989-04-15 |
| GB2185975B (en) | 1990-03-21 |
| HUT42947A (en) | 1987-09-28 |
| FR2597341A1 (fr) | 1987-10-23 |
| DE3701461A1 (de) | 1987-07-23 |
| GB8701281D0 (en) | 1987-02-25 |
| DE3701461C2 (de) | 1992-06-04 |
| AT389227B (de) | 1989-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4161595A (en) | Levulinic acid salt | |
| US4628053A (en) | Stabilized injectable solutions of piroxicam | |
| US5589491A (en) | Injection and injection kit containing omeprazole and its analogs | |
| KR101202649B1 (ko) | 소듐 디클로페낙 및 β-시클로덱스트린을 포함하는 주사용약학 조성물 | |
| EP1386606B1 (de) | Stabile hochkonzentrierte injektion enthaltend ein pyrazolon-derivat | |
| CA1052270A (en) | Oxytetracycline solution for parenteral peroral and local administration and processes for the production thereof | |
| US5169847A (en) | Drug solutions of increased stability and without tissue-damaging effect and process for preparing same | |
| HUT67672A (en) | Sparfloxacine solution and process for producing that | |
| JP3146218B2 (ja) | 点眼剤 | |
| IE50016B1 (en) | Oxytetracycline compositions | |
| CA1160571A (en) | Antitumor compositions | |
| EP0048944B1 (de) | Antimikrobielles Präparat | |
| US20040092587A1 (en) | Freeze-dried preparation of n[o-(p-pivaloyloxybenzenesulfonylamino) benzoyl] glycine monosodium salt tetrahydrate and process for producing the same | |
| EP1039905B1 (de) | Pharmazeutische zusammensetzung enthaltend glyzin als stabilisator | |
| HU195424B (en) | Process for the production of medical solutions containing l-3,4-dihydroxi-phenil-alpha-methil-alanine | |
| US5084276A (en) | Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation | |
| HU199289B (en) | Process for production of liofilized medical compositions containing derivatives of phenil-quinoline-carbonic acid | |
| HU179989B (en) | Process for preparing pharmacological compositions containing r-/+/-1-/1-phenyl-ethyl/-1h-imidazol-5-carboxylic acid ethyl ester for intravenous administration | |
| JP3668225B2 (ja) | Ｏｃｔ製剤 | |
| HU191538B (en) | Process for producing pharmaceutical compositions containing acid additional salts of vinca-dimeres | |
| HU181940B (en) | Process for producing solutions of vincane derivatives for parentheral application | |
| CA1095416A (en) | Pharmaceutical compositions comprising substituted phenyl-amino-alcohol and process for preparing these compositions | |
| US4322424A (en) | Crystalline glucoconate salt of m-AMSA and compositions containing same | |
| US5484785A (en) | Salts of a quinolone-carboxylic acid | |
| US4089968A (en) | Stable solutions of ipronidazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HU90 | Patent valid on 900628 | ||
| HMM4 | Cancellation of final prot. due to non-payment of fee |